The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

NCT06751251 | Active Not Recruiting

• 1 other identifier: PKUPH-sarcoma 20
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate the expression of OX40 (CD134) in sarcomas and its impact on prognosis, with the goal of identifying novel biomarkers for early resistance detection and optimizing treatment strategies for sarcoma patients. Sarcomas are a highly heterogeneous group of malignant tumors, for which current treatment options are often suboptimal in certain patients, and effective biomarkers to guide therapy are lacking. As a T-cell costimulatory receptor, OX40 plays a significant role in immune regulation across various solid tumors and holds promise as a potential therapeutic target. The researcher's team has previously identified high OX40 expression in sarcomas through database analysis and validated the therapeutic efficacy of antibody-drug conjugates targeting OX40 in in vivo experiments using sarcoma cell lines in murine models. This study will evaluate the mRNA expression levels of OX40 in tumor tissues from sarcoma patients and assess OX40 protein expression using immunohistochemical staining. By integrating these findings with clinical and pathological data, the study will explore the potential of OX40 expression levels in tumor tissues as biomarkers for predicting treatment response and prognosis in primary bone tumors. The results aim to provide scientific evidence for the clinical application of OX40-targeted therapies and to propose novel therapeutic strategies to improve survival outcomes in sarcoma patients.

Conditions

Sarcoma; Biomarkers; Progression

Keywords

Sarcoma; OX40; Transcriptomics; Biomarker; CD134; prognosis

Outcome Measures

Primary Outcomes (1)

• correlation of quantity of Protein OX40 Expression with clinical evaluation

  Clinical evaluation according to RECIST 1.1

  6 months

Secondary Outcomes (1)

• correlation of quantity of CD134 RNA with event-free survival

  6 months

Study Arms (2)

OX40 (CD134) expression levels of sarcoma specimens in treatment-native sarcoma patients

Before delivering neoadjuvant chemotherapy, using IHC to test the protein expression of OX40 and using RNA-seq to test the RNA of OX40

Diagnostic Test: IHC: Immunohistochemistry; Genetic: RNA-seq

OX40 (CD134) expression levels of sarcoma specimens in chemotherapy treated sarcoma patients

After neoadiuyant chemotherapy, using IHC to test the protein expression of OX40 and using RNA-seq to test the RNA of OX40

Diagnostic Test: IHC: Immunohistochemistry; Genetic: RNA-seq

Interventions

IHC: Immunohistochemistry DIAGNOSTIC_TEST

Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

OX40 (CD134) expression levels of sarcoma specimens in chemotherapy treated sarcoma patients; OX40 (CD134) expression levels of sarcoma specimens in treatment-native sarcoma patients

RNA-seq GENETIC

RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

OX40 (CD134) expression levels of sarcoma specimens in chemotherapy treated sarcoma patients; OX40 (CD134) expression levels of sarcoma specimens in treatment-native sarcoma patients

Eligibility Criteria

• Age: 8 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Initial treated osteosarcoma patients in PKUPH and later would recieve definitive surgery in PKUPH with complete clinical materials.

You may qualify if:

• Aged 8 years or older.
• Diagnosed with high-grade osteosarcoma or Ewing sarcoma, confirmed through clinical evaluation or histopathological examination. For patients with localized tumors or solitary pulmonary lesions, pathological confirmation is required; for patients with multiple pulmonary metastases, pathological examination is not necessary.
• Treatment-naïve patients who have not received standard first-line chemotherapy regimens for osteosarcoma or Ewing sarcoma.(First-line chemotherapy drugs include high-dose methotrexate, anthracyclines, cisplatin, and ifosfamide. For Ewing sarcoma, the standard first-line regimen is VDC followed by IE.)
• All other examination indicators suggest that the patient is eligible for standardized chemotherapy and surgical treatment for bone tumors.

You may not qualify if:

• Inability to undergo standardized chemotherapy and surgical treatment for bone tumors at this center.
• Refusal to adhere to follow-up according to standardized diagnostic and treatment protocols.
• Any condition that, in the investigator's opinion, may harm the participant or prevent them from meeting or complying with the study requirements.

Sponsors & Collaborators

• Peking University People's Hospital: lead

Study Sites (1)

Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

Location

Related Publications (2)

• Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R. OX40/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024 Sep;43(3):1001-1013. doi: 10.1007/s10555-024-10184-9. Epub 2024 Mar 25.

  PMID: 38526805 BACKGROUND

• Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China. BMC Cancer. 2018 Apr 6;18(1):396. doi: 10.1186/s12885-018-4303-z.

  PMID: 29625604 BACKGROUND

MeSH Terms

Conditions

Sarcoma; Disease Progression

Interventions

RNA-Seq

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Gene Expression Profiling; Genetic Techniques; Investigative Techniques; High-Throughput Nucleotide Sequencing; Sequence Analysis; Sequence Analysis, RNA

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 20, 2024
• First Posted: December 27, 2024
• Study Start: January 1, 2025
• Primary Completion: October 1, 2025
• Study Completion (Estimated): October 1, 2026
• Last Updated: July 10, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)